ALDX Stock Analysis: Buy, Sell, or Hold?
ALDX - Aldeyra Therapeutics, Inc.
$1.52
0.02 (1.33%)
▲
5d:
-2.56%
30d:
-1.94%
90d:
-4.4%
BUY
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When ALDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ALDX shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: ALDX shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ALDX is currently trading at $1.52, which is considered fair relative to its 30-day fair value range of $1.49 to $1.74. From a valuation perspective, the stock is trading at a discount (Forward PE: -5.5) compared to its historical average (12.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ALDX is showing sideways momentum. Immediate support is located at $1.44, while resistance sits at $1.60.
Market Sentiment: ALDX scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $6.60 (+334.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ALDX is showing sideways momentum. Immediate support is located at $1.44, while resistance sits at $1.60.
Market Sentiment: ALDX scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $6.60 (+334.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.49 -
$1.74
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
88.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 334.2% below Wall St target ($6.60)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- BULLISH: Bottoming setup score 63/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$1.49 -
$1.74
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.44
Resistance Level
$1.60
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.53
Wall Street Target
$6.60
(+334.2%)
PE vs Historical
-5.5 vs 12.8
CHEAP
Share & Embed Analysis
Last updated: August 23, 2026 9:21 PM ET
Data refreshes hourly during market hours. Next update: 10:21 PM
Data refreshes hourly during market hours. Next update: 10:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALDX showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Richard Douglas
BUY
70000 shares
2026-03-19
Michael Alfieri
BUY
5000 shares
2026-03-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 40 SELL |
